Genmab — Juli 2023
-
Spændende med J&J’s salgstal. Det plejer at være kl. ca. 12:30, de frigiver regnskabet.
-
Genmab Announces Net Sales of
DARZALEX
(daratumumab) for Second Quarter of 2023 https://www.proinvestor.com/investornyt/1018084/genmab-announces-net-sales-of-darzalex-daratumumab-for-second-quarter-of-2023 -
Johnson & Johnson opjusterer - Darzalex-salg stort set som ventet https://www.proinvestor.com/investornyt/1018102/johnson-johnson-opjusterer-darzalex-salg-stort-set-som-ventet
-
-
Yderligere beføjelser? Det er et bestyrelsesmedlem og ikke et direktionsmedlem. Håber du kender forskellen i den opbygning der ligger mellem direktion og bestyrelse.
-
High-Growth Biopharma: Thriving Through Change & Volatility
To navigate growth, biopharma companies must empower leaders, maintain an agile culture that prioritizes the patient, and invest in R&D.
(www.russellreynolds.com)
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind